Ocular Therapeutix director granted stock, options
Ocular Therapeutix director Charles M. Warden received new equity awards as part of board compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Ocular Therapeutix director Charles M. Warden received new equity awards as part of board compensation. On June 10, 2026, he was granted 14,000 restricted stock units, each representing one share of common stock, boosting his direct holdings to 100,464 shares.
He was also granted options for 44,000 shares of common stock at an exercise price of $8.74 per share, expiring on June 9, 2036. Both the RSUs and options vest in full on the first anniversary of the grant date, or earlier immediately before the next annual stockholder meeting, as long as he remains on the board.
Insider Trade Summary
Grant/Award: 58,000 shares
Grant/Award
2 txns
Insider
Warden Charles M
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 44,000 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 14,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 44,000 contracts (Direct);
Common Stock — 100,464 shares (Direct)
Footnotes (2)
- F1. On June 10, 2026, the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Company"). Each RSU represents a right to receive one share of the Company's common stock. Subject to the reporting person's continued service on the Company's board of directors, the RSUs will vest with respect to 100% of the shares underlying the RSUs on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
- F2. Subject to the reporting person's continued service on the Company's board of directors, the options will vest with respect to 100% of the shares underlying the options on the first anniversary of the grant date or, if earlier, immediately prior to the next annual meeting of stockholders occurring after the grant date.
Key Figures
RSUs granted: 14,000 shares
Options granted: 44,000 shares
Option exercise price: $8.74 per share
+2 more
5 metrics
RSUs granted
14,000 shares
Restricted stock units granted on June 10, 2026
Options granted
44,000 shares
Stock options granted on June 10, 2026
Option exercise price
$8.74 per share
Exercise price for 44,000 stock options
Option expiration
June 9, 2036
Expiration date of granted stock options
Shares held after grant
100,464 shares
Common stock directly held after June 10, 2026 RSU grant
Key Terms
restricted stock units ("RSUs"), 2021 Stock Incentive Plan, Stock Option (Right to Buy), vesting, +1 more
5 terms
restricted stock units ("RSUs") financial
"the reporting person was granted restricted stock units ("RSUs") under the 2021 Stock Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2021 Stock Incentive Plan financial
"RSUs under the 2021 Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc."
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting financial
"the RSUs will vest with respect to 100% of the shares underlying the RSUs"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"immediately prior to the next annual meeting of stockholders occurring after the grant date"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Ocular Therapeutix (OCUL) director Charles M. Warden receive in this Form 4 filing?
Director Charles M. Warden received equity awards consisting of 14,000 restricted stock units and options for 44,000 shares. These grants are part of his board compensation and give him rights to future common stock, subject to vesting conditions.
What are the terms of the stock options granted to the Ocular Therapeutix (OCUL) director?
The director received stock options for 44,000 shares of Ocular Therapeutix common stock at an exercise price of $8.74 per share. These options expire on June 9, 2036 and are subject to vesting based on his continued board service.
When do the Ocular Therapeutix (OCUL) RSUs and options granted to the director vest?
Both the 14,000 restricted stock units and the 44,000 stock options vest 100% on the first anniversary of the June 10, 2026 grant date, or earlier immediately before the next annual stockholder meeting, provided the director continues serving on the board.
Are the Ocular Therapeutix (OCUL) equity awards to the director open-market purchases or compensation grants?
The reported transactions are compensation grants, not open-market purchases. The Form 4 uses code “A” for grant or award, and both the RSUs and options were issued at a price of $0.00 per unit as part of the company’s stock incentive plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates